PUBLIC COMPANY
save$AVBPArriVent BioPharma, Inc.
$AVBP29.18-2.80%Newtown Square, PA, USupdated 3h ago
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
5
approvals ytd
2
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 31Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase1Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- phase3Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- phase1A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- phase1Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
- phase3Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
🐶 Hiring Signal
News
- New Taiho, Cullinan data heats up lung cancer drug battleThe findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.biopharma_dive · 7d ago
Data sources
last refreshed just now
Found something off?
comments(0)
5-min edit window · permanent after that